GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Compugen Ltd (NAS:CGEN) » Definitions » ROE % Adjusted to Book Value

Compugen (Compugen) ROE % Adjusted to Book Value : 24.32% (As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Compugen ROE % Adjusted to Book Value?

Compugen's ROE % for the quarter that ended in Dec. 2023 was 65.42%. Compugen's PB Ratio for the quarter that ended in Dec. 2023 was 2.69. Compugen's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was 24.32%.


Compugen ROE % Adjusted to Book Value Historical Data

The historical data trend for Compugen's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Compugen ROE % Adjusted to Book Value Chart

Compugen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.84 -4.44 -8.68 -45.69 -9.74

Compugen Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -19.64 -57.80 -34.91 -44.42 24.32

Competitive Comparison of Compugen's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Compugen's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Compugen's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Compugen's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Compugen's ROE % Adjusted to Book Value falls into.



Compugen ROE % Adjusted to Book Value Calculation

Compugen's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-26.19% / 2.69
=-9.74%

Compugen's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=65.42% / 2.69
=24.32%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Compugen ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Compugen's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Compugen (Compugen) Business Description

Industry
Traded in Other Exchanges
Address
26 Harokmim Street, Building D, Azrieli Center, Holon, ISR, 5885849
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.

Compugen (Compugen) Headlines

From GuruFocus

Compugen Reports Second Quarter 2023 Results

By PRNewswire 08-07-2023